Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,accountsPayable,deferredLongTermLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,HARP,90928000.0,32523800,,,-16764000,,-16764000,4335000,-12433000,-16768000,-16768000,,,,,,0,5838000,22606000,18271000,4000,,-16764000,-16764000,337484000.0,105249000.0,90928000.0,34819000.0,196177000.0,4000.0,-246558000.0,39156000.0,-2000.0,747000.0,77413000.0,54694000.0,-2000.0,15558000.0,175678000.0,4194000.0,93604000.0,1997000.0,,69690000.0,-6483000.0,69690000.0,2954000.0,-46935000.0,2954000.0,6078000.0,-66566000.0,749000.0,2866000.0,,,120984000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,9.52,1630526402,0.040000916,9.5,9.66,9.38,127277,-2.659218,3.156,10.150286,-0.63028526,-0.06209532,16.583624,-7.0636234,-0.42593968,309626592,-4.6213593,3.0164769,15,America/New_York,EDT,False,False,USD,-3.58,us_market,"Harpoon Therapeutics, Inc.",NMS,PREPRE,2,-0.10504442,1630527676,9.51,-0.010000229,0.42195058,9.38 - 9.66,9.48,0.0,0.0,9,8,finmb_413195889,NasdaqGS,"Harpoon Therapeutics, Inc.",USD,529807,323157,1.2590008,0.15240295,8.261 - 25.235,-15.715,-0.62274617,8.261,25.235,1620317040,1635850740,0,1636372800,-3.708,-2.06,-14400000,0.79,,,25.24,8.26,10.15,16.58,529.81k,323.16k,32.52M,,17.73M,7.74%,88.35%,2.8M,5.14,9.20%,8.59%,1.96M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-204.61%,-17.06%,-126.70%,26.23M,0.92,111.40%,-35.12M,-51.51M,-103.15M,-3.71,,171.02M,5.24,12.94M,14.23,3.21,3.16,-113.3M,-10.22M,Value,94080,Healthcare,88,8,3,"Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 7400,CA,8,1609372800,1625097600,7,United States,http://www.harpoontx.com,86400,7,131 Oyster Point Boulevard,Biotechnology,Suite 300
t-1,HARP,102380000.0,32523800,,,-61724000,,-61724000,4604000,-7209000,-11813000,-11813000,,,,,,0,9007000,20820000,16216000,-49911000,,-61724000,-61724000,332188000.0,158937000.0,102380000.0,80795000.0,261317000.0,4000.0,-229795000.0,48973000.0,-17000.0,805000.0,71335000.0,98163000.0,-17000.0,16242000.0,234281000.0,9989000.0,158078000.0,2641000.0,,-39855000.0,-7937000.0,-39900000.0,108142000.0,48300000.0,108142000.0,50165000.0,-18077000.0,649000.0,2635000.0,-45000.0,,136118000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,9.52,1630526402,0.040000916,9.5,9.66,9.38,127277,-2.659218,3.156,10.150286,-0.63028526,-0.06209532,16.583624,-7.0636234,-0.42593968,309626592,-4.6213593,3.0164769,15,America/New_York,EDT,False,False,USD,-3.58,us_market,"Harpoon Therapeutics, Inc.",NMS,PREPRE,2,-0.10504442,1630527676,9.51,-0.010000229,0.42195058,9.38 - 9.66,9.48,0.0,0.0,9,8,finmb_413195889,NasdaqGS,"Harpoon Therapeutics, Inc.",USD,529807,323157,1.2590008,0.15240295,8.261 - 25.235,-15.715,-0.62274617,8.261,25.235,1620317040,1635850740,0,1636372800,-3.708,-2.06,-14400000,0.79,,,25.24,8.26,10.15,16.58,529.81k,323.16k,32.52M,,17.73M,7.74%,88.35%,2.8M,5.14,9.20%,8.59%,1.96M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-204.61%,-17.06%,-126.70%,26.23M,0.92,111.40%,-35.12M,-51.51M,-103.15M,-3.71,,171.02M,5.24,12.94M,14.23,3.21,3.16,-113.3M,-10.22M,Value,94080,Healthcare,88,8,3,"Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 7400,CA,8,1609372800,1625097600,7,United States,http://www.harpoontx.com,86400,7,131 Oyster Point Boulevard,Biotechnology,Suite 300
t-2,HARP,53839000.0,32523800,,,-11357000,,-11357000,3924000,-7573000,-11497000,-11497000,,,,,,0,7492000,18989000,15065000,140000,,-11357000,-11357000,221904000.0,117753000.0,53839000.0,31528000.0,171592000.0,3000.0,-168071000.0,57522000.0,3000.0,1121000.0,21170000.0,47918000.0,3000.0,16771000.0,129754000.0,23946000.0,104860000.0,1572000.0,600000.0,10503000.0,-7905000.0,10445000.0,3241000.0,1871000.0,3241000.0,-1481000.0,-15167000.0,637000.0,1587000.0,-58000.0,,81836000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,9.52,1630526402,0.040000916,9.5,9.66,9.38,127277,-2.659218,3.156,10.150286,-0.63028526,-0.06209532,16.583624,-7.0636234,-0.42593968,309626592,-4.6213593,3.0164769,15,America/New_York,EDT,False,False,USD,-3.58,us_market,"Harpoon Therapeutics, Inc.",NMS,PREPRE,2,-0.10504442,1630527676,9.51,-0.010000229,0.42195058,9.38 - 9.66,9.48,0.0,0.0,9,8,finmb_413195889,NasdaqGS,"Harpoon Therapeutics, Inc.",USD,529807,323157,1.2590008,0.15240295,8.261 - 25.235,-15.715,-0.62274617,8.261,25.235,1620317040,1635850740,0,1636372800,-3.708,-2.06,-14400000,0.79,,,25.24,8.26,10.15,16.58,529.81k,323.16k,32.52M,,17.73M,7.74%,88.35%,2.8M,5.14,9.20%,8.59%,1.96M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-204.61%,-17.06%,-126.70%,26.23M,0.92,111.40%,-35.12M,-51.51M,-103.15M,-3.71,,171.02M,5.24,12.94M,14.23,3.21,3.16,-113.3M,-10.22M,Value,94080,Healthcare,88,8,3,"Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 7400,CA,8,1609372800,1625097600,7,United States,http://www.harpoontx.com,86400,7,131 Oyster Point Boulevard,Biotechnology,Suite 300
t-3,HARP,60742000.0,32523800,,,-13307000,,-13307000,4428000,-9164000,-13592000,-13592000,,,,,,0,3893000,17485000,13057000,285000,,-13307000,-13307000,217326000.0,122579000.0,60742000.0,31637000.0,183321000.0,3000.0,-156714000.0,64675000.0,127000.0,888000.0,22651000.0,45214000.0,127000.0,17195000.0,157724000.0,7514000.0,132156000.0,1779000.0,,801000.0,-3676000.0,331000.0,1069000.0,1227000.0,748000.0,-12087000.0,-13487000.0,630000.0,1639000.0,-470000.0,321000.0,112510000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,9.52,1630526402,0.040000916,9.5,9.66,9.38,127277,-2.659218,3.156,10.150286,-0.63028526,-0.06209532,16.583624,-7.0636234,-0.42593968,309626592,-4.6213593,3.0164769,15,America/New_York,EDT,False,False,USD,-3.58,us_market,"Harpoon Therapeutics, Inc.",NMS,PREPRE,2,-0.10504442,1630527676,9.51,-0.010000229,0.42195058,9.38 - 9.66,9.48,0.0,0.0,9,8,finmb_413195889,NasdaqGS,"Harpoon Therapeutics, Inc.",USD,529807,323157,1.2590008,0.15240295,8.261 - 25.235,-15.715,-0.62274617,8.261,25.235,1620317040,1635850740,0,1636372800,-3.708,-2.06,-14400000,0.79,,,25.24,8.26,10.15,16.58,529.81k,323.16k,32.52M,,17.73M,7.74%,88.35%,2.8M,5.14,9.20%,8.59%,1.96M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,-204.61%,-17.06%,-126.70%,26.23M,0.92,111.40%,-35.12M,-51.51M,-103.15M,-3.71,,171.02M,5.24,12.94M,14.23,3.21,3.16,-113.3M,-10.22M,Value,94080,Healthcare,88,8,3,"Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 7400,CA,8,1609372800,1625097600,7,United States,http://www.harpoontx.com,86400,7,131 Oyster Point Boulevard,Biotechnology,Suite 300
